Regeneron Pharmaceuticals, Inc. — Q1 2019 Form 10-Q Summary
Business context and reporting period
Regeneron is an integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines. The filing covers the three months ended March 31, 2019, with comparative results for the three months ended March 31, 2018. The interim financial statements are unaudited.
Key commercial products included EYLEA, Libtayo, and ARCALYST. Regeneron also reported collaboration revenue from Sanofi, Bayer, and Teva. EYLEA remained the principal revenue driver; U.S. EYLEA sales represented 63% of total revenue in the quarter.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Total revenue | $1,711.8 million | $1,511.5 million | 13.3% increase |
| Net product sales | $1,104.4 million | $987.9 million | 11.8% increase |
| Income from operations | $480.0 million | $567.2 million | 15.4% decrease |
| Net income | $461.1 million | $478.0 million | 3.5% decrease |
| Diluted earnings per share | $3.99 | $4.16 | 4.1% decrease |
| Operating margin | 28.0% | 37.5% | Lower |
| Net margin | 26.9% | 31.6% | Lower |
| Effective tax rate | 15.6% | 18.3% | Lower |
| Net cash from operating activities | $897.0 million | $618.8 million | $278.2 million increase |
Revenue growth was led by U.S. EYLEA sales of $1,074.1 million, up $90.1 million, and initial Libtayo sales of $26.8 million. Bayer collaboration revenue increased to $276.2 million from $247.9 million, while Sanofi collaboration revenue increased to $246.4 million from $189.5 million.
Operating expenses increased 30.5% to $1,231.8 million. Research and development expense rose to $641.8 million, selling, general, and administrative expense rose to $410.8 million, and collaboration and contract manufacturing costs increased to $108.3 million. Average headcount increased to 7,448 from 6,401. Non-cash compensation expense was $107.9 million.
Operating cash flow benefited substantially from a $461.9 million Sanofi payment related to the amended immuno-oncology discovery agreement and a $426.5 million increase in deferred revenue. Net cash used in investing activities was $776.1 million, including $1,040.2 million of security purchases and $74.3 million of capital expenditures. Capital expenditures for full-year 2019 were expected to be $410 million to $475 million.
At March 31, 2019, cash and cash equivalents were $1,708.5 million, current marketable securities were $1,523.9 million, and noncurrent marketable securities were $2,339.8 million. Working capital was $5,417.2 million. Finance lease liabilities were $709.9 million, and the company had $750.0 million of borrowing availability under its revolving credit facility. Total liabilities were $3,410.1 million and stockholders’ equity was $9,444.7 million.
Material changes versus the prior comparable period
- EYLEA U.S. sales increased 9.2%, primarily from higher volume, partly offset by higher sales-related deductions.
- Libtayo generated $26.8 million of U.S. product sales following its September 2018 approval.
- Sanofi collaboration revenue increased primarily because of higher reimbursement and commercialization activity related to the antibody collaboration and higher Dupixent sales, partly offset by lower immuno-oncology research and development reimbursements.
- Research and development expense increased $143.2 million, including higher spending on Libtayo, other clinical programs, indirect personnel costs, and clinical manufacturing.
- Operating margin declined materially as expense growth exceeded revenue growth.
- Operating cash flow increased substantially, primarily due to the Sanofi payment and higher deferred revenue.
- The company adopted ASC 842, recognizing $33.2 million of operating lease right-of-use assets at January 1, 2019. The adoption did not materially affect the financial statements.
- Regeneron purchased 131,115 shares from Sanofi during the quarter for total consideration of approximately $54.0 million, including $44.0 million settled through a credit against amounts owed by Sanofi and $10.0 million paid in cash.
Guidance, outlook, commentary, risks, and unusual items
Management stated that continued profitability and positive cash flow depend significantly on the continued success of EYLEA. The company expected substantial ongoing research and development, commercialization, manufacturing, and capital expenditures. No full-year revenue or earnings guidance was provided in the filing text.
Near-term development and regulatory milestones included FDA decisions for EYLEA diabetic retinopathy and pre-filled syringe applications; additional Dupixent indications and devices; continued Libtayo development; and clinical results or progress for fasinumab, evinacumab, garetosmab, REGN3500, REGN1979, REGN-EB3, and other pipeline programs.
In April 2019, after the quarter-end, Regeneron entered into a strategic collaboration with Alnylam. The arrangement required a $400.0 million upfront payment and an approximately $400.0 million purchase of Alnylam common stock, expected in the second quarter of 2019.
Material contingencies included patent litigation involving Praluent, Dupixent, EYLEA, and the company’s antibody-generation technology. In the United States, a February 2019 jury verdict generally favored Amgen regarding certain Praluent patent claims, and Amgen sought a permanent injunction. The company also disclosed a Department of Justice investigation concerning patient assistance programs and related documents; Regeneron was cooperating.
Principal business risks included dependence on EYLEA, competition and potential biosimilars, pricing and reimbursement pressure, regulatory and clinical-development uncertainty, manufacturing capacity and compliance, reliance on Sanofi and Bayer, customer concentration, intellectual-property litigation, investment-market volatility, and potential changes in healthcare regulation.
Important facts for investors to verify
- Whether EYLEA sales growth can offset competitive pressure, pricing changes, reimbursement constraints, and potential biosimilar competition.
- The trajectory of Libtayo and Dupixent sales, including the effect of expanded indications and commercialization spending.
- Progress and outcomes of the disclosed regulatory submissions and clinical milestones.
- The ultimate outcome and potential commercial impact of the Praluent, Dupixent, EYLEA, and antibody-technology patent proceedings.
- The financial and operational impact of the Alnylam collaboration and its $800.0 million aggregate upfront and equity commitments.
- Whether capital expenditures remain within the disclosed $410 million to $475 million 2019 range and whether manufacturing expansion meets anticipated demand.
- The sustainability of operating cash flow, particularly excluding the one-time or timing-related Sanofi payment and deferred-revenue increase.
- Exposure to Sanofi and Bayer collaboration terms, including termination rights, funding obligations, and profit-sharing estimates.